- Schrodinger's software platform has transformed the way therapeutics are discovered.
- The platform is licensed to pharmaceuticals, biotechs, materials companies, universities, and government labs worldwide.
- In addition, currently at preclinical stage, the company is working on three programs covering Leukemia, cancers and DNA damage response.
- Despite highly recurrent software sales, variability of the quarter-to-quarter drug discovery income from partners does constitute risks in terms of revenue misses, thereby constituting downside risks.
- An investment makes sense for someone who is looking for biotech exposure, while at the same time benefiting from a highly efficient and expanding software platform.
For further details see:
Schrodinger: An Investment In Drug Discovery In Addition To Software Sales